Leveraging allosteric biochemistry for patients

Adoram is a start-up/spin-off from the University of Geneva with  know-how in developing allosteric modulators of a validated cancer immunotherapy target, A2AR.

The start-up management & co-founders were brought together by their passion for addressing unmet medical needs

“Supported by a strong team in place for new asset development”